Organ Recovery Systems (ORS), a global leading provider of organ perfusion devices and services, recently announced that the New England Journal of Medicine (NEJM) published detailed, 10-year follow-up data from a 2009 Moers et al. landmark clinical study. The 2009 study, a multicenter, randomized, paired-kidney clinical trial following 672 recipients, reinforced the long-term impact of hypothermic machine perfusion (HMP) using LifePort Kidney Transporter. This extensive follow-up builds on the landmark 2009 Moers et al. study, which originally demonstrated the benefits of HMP in kidney transplantation.
In addition, there was an interim Moers et al. 2012 study that demonstrated significantly better 3-year graft survival with HMP using LifePort Kidney Transporter, especially in ECD kidneys.
Overall response was 99%, and complete 10-year data was available for 92% of transplant recipients. This 10-year follow up report substantiates the findings from the original clinical trials, as well as the 3-year follow up, supporting preservation on LifePort Kidney Transporter as the improved standard of care for kidney transplant.
Dr. Cyril Moers, author of the landmark clinical study, stated, “With this third NEJM publication, and after many other high-impact publications and presentations, we have come to the end of an amazing scientific journey that started in 2004 and has since then been revolutionizing the way deceased-donor kidneys are being preserved around the globe. Even though there have been many other studies on renal HMP since the MP Trial, no single one of them has been as influential as our collaborative endeavor.”
The decade-long data confirms and strengthens earlier findings, showing that kidney preservation with LifePort significantly reduces delayed graft function and improves long-term graft survival, particularly in expanded-criteria donor (ECD) kidneys. Specifically, the data demonstrates that ECD kidneys perfused on LifePort Kidney Transporter have improved graft survival at 10 years at 69.6% vs. 60.1% with SCS. Additionally, DCD kidneys perfused on LifePort Kidney Transporter also have improved graft survival at 10 years at 81.4% vs. 75.61% with SCS.
Dr. Jacques Pirenne, transplant surgeon and Professor at KU Leuven , said, “Having now, for the first time, long term follow up data from a large RCT demonstrating the impact of HMP on Graft Survival being sustained up to 10 yrs post-op is not only excellent news for renal transplant recipients. The fact that up to 10 yrs post-op fewer patients need to return to dialysis also fuels the recommendation from a cost-effectiveness perspective for using HMP as standard preservation method for (extended criteria) donor kidneys.”
Matt Copithorne, Vice President of Sales and Marketing at ORS, said, “This is the first and only prospective, randomized clinical trial evaluating an HMP device in kidney transplantation with 10-year outcomes. For patients awaiting a second chance at life, these results offer real hope. More successful transplants and longer-lasting grafts mean more lives saved and a deeper honoring of the gift of donation. Organ Recovery Systems is proud to lead the way in advancing transplant innovation and making every donation count.”
ORS continues to lead and innovate in the organ preservation space. For over 20 years, LifePort Kidney Transporter has been the standard for kidney hypothermic machine perfusion, used around the globe to improve kidney transplantation for the patients that need it.
*Sponsored content. Organ Recovery Systems is a 2025 Advocate Level Corporate Partner of The Alliance.
